Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus

Kevin R. Kelly, Claudia M. Espitia, Weiguo Zhao, Erik Wendlandt, Guido Tricot, Fenghuang Zhan, Jennifer S. Carew, Steffan T. Nawrocki

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Despite the development of several new agents for multiple myeloma (MM) therapy over the last decade, drug resistance continues to be a significant problem. Patients with relapsed/refractory disease have high mortality rates and desperately need new precision approaches that directly target specific molecular features that are prevalent in the refractory setting. Reolysin is a proprietary formulation of reovirus for cancer therapy that has demonstrated efficacy in multiple clinical trials. Its selective effects against solid tumors have been largely attributed to RAS-mediated control of reovirus replication. However, the mechanisms regulating its preferential anti-neoplastic effects in MM and other hematological malignancies have not been rigorously studied. Here we report that the reovirus receptor, junctional adhesion molecule-A (JAM-A) is highly expressed in primary cells from patients with MM and the majority of MM cell lines compared to normal controls. A series of experiments demonstrated that JAM-A expression, rather than RAS, was required for Reolysin-induced cell death in MM models. Notably, analysis of paired primary MM specimens revealed that JAM-A expression was significantly increased at relapse compared to diagnosis. Two different models of acquired resistance to bortezomib also displayed both higher JAM-A expression and elevated sensitivity to Reolysin compared to parental cells, suggesting that Reolysin may be an effective agent for patients with relapsed/refractory disease due to their high JAM-A levels. Taken together, these findings support further investigation of Reolysin for the treatment of patients with relapsed/refractory MM and of JAM-A as a predictive biomarker for sensitivity to Reolysin-induced cell death.

Original languageEnglish (US)
Pages (from-to)41275-41289
Number of pages15
JournalOncotarget
Volume6
Issue number38
DOIs
StatePublished - 2015

Fingerprint

Junctional Adhesion Molecule A
Multiple Myeloma
Cell Death
Proxy
Hematologic Neoplasms
Drug Resistance
Neoplasms
Therapeutics
Biomarkers
Clinical Trials

Keywords

  • Bortezomib
  • JAM-A
  • Myeloma
  • NOXA
  • Reovirus

ASJC Scopus subject areas

  • Oncology

Cite this

Kelly, K. R., Espitia, C. M., Zhao, W., Wendlandt, E., Tricot, G., Zhan, F., ... Nawrocki, S. T. (2015). Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus. Oncotarget, 6(38), 41275-41289. https://doi.org/10.18632/oncotarget.5753

Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus. / Kelly, Kevin R.; Espitia, Claudia M.; Zhao, Weiguo; Wendlandt, Erik; Tricot, Guido; Zhan, Fenghuang; Carew, Jennifer S.; Nawrocki, Steffan T.

In: Oncotarget, Vol. 6, No. 38, 2015, p. 41275-41289.

Research output: Contribution to journalArticle

Kelly, KR, Espitia, CM, Zhao, W, Wendlandt, E, Tricot, G, Zhan, F, Carew, JS & Nawrocki, ST 2015, 'Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus', Oncotarget, vol. 6, no. 38, pp. 41275-41289. https://doi.org/10.18632/oncotarget.5753
Kelly, Kevin R. ; Espitia, Claudia M. ; Zhao, Weiguo ; Wendlandt, Erik ; Tricot, Guido ; Zhan, Fenghuang ; Carew, Jennifer S. ; Nawrocki, Steffan T. / Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus. In: Oncotarget. 2015 ; Vol. 6, No. 38. pp. 41275-41289.
@article{0b984312d92a46ac800760001236e6f7,
title = "Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus",
abstract = "Despite the development of several new agents for multiple myeloma (MM) therapy over the last decade, drug resistance continues to be a significant problem. Patients with relapsed/refractory disease have high mortality rates and desperately need new precision approaches that directly target specific molecular features that are prevalent in the refractory setting. Reolysin is a proprietary formulation of reovirus for cancer therapy that has demonstrated efficacy in multiple clinical trials. Its selective effects against solid tumors have been largely attributed to RAS-mediated control of reovirus replication. However, the mechanisms regulating its preferential anti-neoplastic effects in MM and other hematological malignancies have not been rigorously studied. Here we report that the reovirus receptor, junctional adhesion molecule-A (JAM-A) is highly expressed in primary cells from patients with MM and the majority of MM cell lines compared to normal controls. A series of experiments demonstrated that JAM-A expression, rather than RAS, was required for Reolysin-induced cell death in MM models. Notably, analysis of paired primary MM specimens revealed that JAM-A expression was significantly increased at relapse compared to diagnosis. Two different models of acquired resistance to bortezomib also displayed both higher JAM-A expression and elevated sensitivity to Reolysin compared to parental cells, suggesting that Reolysin may be an effective agent for patients with relapsed/refractory disease due to their high JAM-A levels. Taken together, these findings support further investigation of Reolysin for the treatment of patients with relapsed/refractory MM and of JAM-A as a predictive biomarker for sensitivity to Reolysin-induced cell death.",
keywords = "Bortezomib, JAM-A, Myeloma, NOXA, Reovirus",
author = "Kelly, {Kevin R.} and Espitia, {Claudia M.} and Weiguo Zhao and Erik Wendlandt and Guido Tricot and Fenghuang Zhan and Carew, {Jennifer S.} and Nawrocki, {Steffan T.}",
year = "2015",
doi = "10.18632/oncotarget.5753",
language = "English (US)",
volume = "6",
pages = "41275--41289",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "38",

}

TY - JOUR

T1 - Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus

AU - Kelly, Kevin R.

AU - Espitia, Claudia M.

AU - Zhao, Weiguo

AU - Wendlandt, Erik

AU - Tricot, Guido

AU - Zhan, Fenghuang

AU - Carew, Jennifer S.

AU - Nawrocki, Steffan T.

PY - 2015

Y1 - 2015

N2 - Despite the development of several new agents for multiple myeloma (MM) therapy over the last decade, drug resistance continues to be a significant problem. Patients with relapsed/refractory disease have high mortality rates and desperately need new precision approaches that directly target specific molecular features that are prevalent in the refractory setting. Reolysin is a proprietary formulation of reovirus for cancer therapy that has demonstrated efficacy in multiple clinical trials. Its selective effects against solid tumors have been largely attributed to RAS-mediated control of reovirus replication. However, the mechanisms regulating its preferential anti-neoplastic effects in MM and other hematological malignancies have not been rigorously studied. Here we report that the reovirus receptor, junctional adhesion molecule-A (JAM-A) is highly expressed in primary cells from patients with MM and the majority of MM cell lines compared to normal controls. A series of experiments demonstrated that JAM-A expression, rather than RAS, was required for Reolysin-induced cell death in MM models. Notably, analysis of paired primary MM specimens revealed that JAM-A expression was significantly increased at relapse compared to diagnosis. Two different models of acquired resistance to bortezomib also displayed both higher JAM-A expression and elevated sensitivity to Reolysin compared to parental cells, suggesting that Reolysin may be an effective agent for patients with relapsed/refractory disease due to their high JAM-A levels. Taken together, these findings support further investigation of Reolysin for the treatment of patients with relapsed/refractory MM and of JAM-A as a predictive biomarker for sensitivity to Reolysin-induced cell death.

AB - Despite the development of several new agents for multiple myeloma (MM) therapy over the last decade, drug resistance continues to be a significant problem. Patients with relapsed/refractory disease have high mortality rates and desperately need new precision approaches that directly target specific molecular features that are prevalent in the refractory setting. Reolysin is a proprietary formulation of reovirus for cancer therapy that has demonstrated efficacy in multiple clinical trials. Its selective effects against solid tumors have been largely attributed to RAS-mediated control of reovirus replication. However, the mechanisms regulating its preferential anti-neoplastic effects in MM and other hematological malignancies have not been rigorously studied. Here we report that the reovirus receptor, junctional adhesion molecule-A (JAM-A) is highly expressed in primary cells from patients with MM and the majority of MM cell lines compared to normal controls. A series of experiments demonstrated that JAM-A expression, rather than RAS, was required for Reolysin-induced cell death in MM models. Notably, analysis of paired primary MM specimens revealed that JAM-A expression was significantly increased at relapse compared to diagnosis. Two different models of acquired resistance to bortezomib also displayed both higher JAM-A expression and elevated sensitivity to Reolysin compared to parental cells, suggesting that Reolysin may be an effective agent for patients with relapsed/refractory disease due to their high JAM-A levels. Taken together, these findings support further investigation of Reolysin for the treatment of patients with relapsed/refractory MM and of JAM-A as a predictive biomarker for sensitivity to Reolysin-induced cell death.

KW - Bortezomib

KW - JAM-A

KW - Myeloma

KW - NOXA

KW - Reovirus

UR - http://www.scopus.com/inward/record.url?scp=84951112756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951112756&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.5753

DO - 10.18632/oncotarget.5753

M3 - Article

C2 - 26513296

AN - SCOPUS:84951112756

VL - 6

SP - 41275

EP - 41289

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 38

ER -